We know how hard it can be to deal with life’s daily challenges when your mental health is suffering – especially when conventional medicine and therapy aren’t providing the results you need.
BE YOURSELF AGAIN
A Breakthrough in Mental Health
Safe & proven, medically supervised ketamine treatments
WE'RE HERE FOR YOU
- You’ve tried everything, yet nothing seems to work.
- The side effects from SSRIs and traditional antidepressants can become intolerable.
- Your relationships, work life, and financial wellbeing suffer.
- You’re feeling lost and hopeless
We’ve been there too, and you’re not alone.
That's Why We Created KetaMD
KetaMD is a HIPAA-compliant telemedicine platform providing convenient and effective ketamine treatments for depression and related mental health conditions.
Safe and secure, our fully virtual program is administered at home, alongside licensed medical providers, so you can focus on your path to healing where you feel most comfortable.
KETAMINE TREATMENT:
BACKED BY SCIENCE
This breakthrough treatment has been scientifically proven to rapidly reduce feelings of depression, even for those who suffer from treatment-resistant symptoms.
- “Lifted depression in as little as two hours in people with treatment resistant depression.” – National Institutes of Health
- “Helps regenerate synaptic connections between brain cells damaged by stress and depression.” – Yale School of Medicine
- “Ketamine produces rapid and sustained antidepressant effects in treatment resistant patients” – Psychiatry and Clinical Neurosciences
OUR ANSWER TO A GLOBAL
MENTAL HEALTH CRISIS
We’ve teamed with the world’s foremost experts to make this safe, innovative treatment accessible to the millions of people affected by what is now a global mental health crisis.
DESIGNED WITH
MENTAL HEALTH EXPERTS
Our medical advisory team is comprised of some of the world’s most prominent experts in their field. KetaMD’s program and our clinical protocols have been developed with the highest standard of care to ensure your safety and the best outcomes.
Dr. Roger McIntyre is the chairman and chief executive officer of Braxia Scientific. Dr. McIntyre is the world’s top-ranked depression researcher and has almost 25 years of providing care and conducting research, along with drug discovery and development, for persons with depression and related disorders.
He is a professor of psychiatry and pharmacology at the University of Toronto and Head of the Mood Disorders, Psychopharmacology Unit at the University Health Network in Toronto. Dr. McIntyre serves as the Executive Director of the Brain and Cognition Discovery Foundation in Toronto and is the Director and Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance. He was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020 and 2021 as one of “The World’s Most Influential Scientific Minds”.
Dr. McIntyre has authored/co-authored more than 785 publications, and has edited and/or co-edited several textbooks on mood disorders. He is involved in multiple research endeavors which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders.
Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders.
Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.
Dr. Joshua Rosenblat is the medical director and researcher at the Canadian Rapid Treatment Centre of Excellence (CRTCE). Dr. Rosenblat is also a clinician-scientist at the Mood Disorders Psychopharmacology Unit (MDPU) at Toronto Western Hospital and at the University of Toronto.
Dr. Rosenblat has treated hundreds of patients with ketamine infusions for treatment-resistant depression, bipolar disorder, suicidality and PTSD. He also continues to conduct numerous research studies to better understand how the use of ketamine may be optimized in psychiatry to allow for rapid and sustained symptom relief and full functional recovery.
Dr. Rosenblat’s primary clinical focus is treatment-resistant unipolar and bipolar depression and his research focus is conducting clinical trials to identify and evaluate novel psychopharmacological interventions for mood disorders that may substantially improve patient outcomes. He has authored and co-authored over a hundred journal articles and textbook chapters in prestigious journals, such as the New England Journal of Medicine, JAMA Psychiatry, the American Journal of Psychiatry and the Journal of Clinical Psychiatry. He has received numerous local, national and international grants and awards for his research in mood disorders.
Dr. Rosenblat is also actively involved in teaching medical students and residents locally and nationally.
Dr. Sanjiv Chopra is a Professor of Medicine at Harvard Medical School and a Senior Consultant in Hepatology at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. Like his brother Deepak Chopra, Dr. Chopra is a bestselling author and sought-after motivational speaker. He has scores of publications to his credit, including seven books that have been translated into multiple languages.
Dr. Chopra is also the Editor-in-Chief of the Hepatology Section of UpToDate, the most widely used electronic textbook in the world (subscribed to by an estimated 950,000 physicians worldwide).
Dr. Yousif A-Rahim is the Chief Medical Officer for Covenant Physician Partners, a physician services company partnering with more than 1,800 leading providers across the country to grow thriving practices. As a lecturer in Medicine at Harvard Medical School, Dr. A- Rahim has authored many articles published in medical journals and delivered presentations to fellow physicians around the world.
Dr. A-Rahim is also a healthcare investor and international healthcare entrepreneur.
Dr. Daniel Kang is a Los Angeles native and a UC Berkeley grad. Upon graduating, he worked at a non-profit community health center where his data research and collaboration with the state of California helped to increase resources for underserved communities. He attended medical school at Albert Einstein College of Medicine, and completed his residency in Anesthesiology at Brigham and Women’s Hospital, an institution of Harvard Medical School.
In pursuit of providing anesthetic care across all ages, he continued his training as a pediatric anesthesiology fellow at Children’s Hospital of Los Angeles. Dr. Kang is passionate about improving access to quality care and creating efficiencies through the use of technology. As such, he has various publications on optimization of patient experience, automation of preoperative triage, and identifying risk factors for patient safety.
As Chief Medical Officer of KetaMD, he is committed to creating the gold standard for at-home ketamine treatment with an emphasis on patient experience and best-in-class integration. His mission is not only to deliver ketamine safely, but to create lasting change and improvement in people’s lives by sharing tools and teachings for success.
